Abstract | BACKGROUND: METHODS: RESULTS: The response rate after 2 cycles of chemotherapy was 34% (complete response, 13.8%; partial response, 20.7%). Myelosuppression was the dominant toxicity; 2 patients had toxic deaths related to thrombocytopenia with trauma. The 5-year overall survival (OS) was 49% +/- 7%, and the progression-free survival (PFS) was 31% +/- 7%, with a median follow-up of 11.4 years (range, 5.2-15.0 years). For medulloblastoma, the 5-year PFS was 26% +/- 9%; for EP it was 33% +/- 10%; for CPCA it was 80% +/- 18%; and for primitive neuroectodermal and atypical teratoid rhabdoid tumors it was 0%. Localized EP patients with gross total resection who did not undergo radiotherapy had a 5-year PFS of 57% +/- 17% and OS of 71% +/- 16%. Two patients developed late second malignancies; 1 was associated with germline p53 mutation. CONCLUSIONS: The results confirm that carboplatin has similar activity to cisplatin in otherwise similar regimens. Five-year survival data are comparable to those reported in other recent studies, including high-dose chemotherapy studies. Of note is the marked activity in CPCA and gross totally resected EP.
|
Authors | Maryam Fouladi, Sri Gururangan, Albert Moghrabi, Peter Phillips, Lindsey Gronewold, Dana Wallace, Robert A Sanford, Amar Gajjar, Larry E Kun, Richard Heideman |
Journal | Cancer
(Cancer)
Vol. 115
Issue 14
Pg. 3243-53
(Jul 15 2009)
ISSN: 0008-543X [Print] United States |
PMID | 19484793
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Etoposide
- Cyclophosphamide
- Carboplatin
|
Topics |
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Carboplatin
(administration & dosage, adverse effects)
- Central Nervous System Neoplasms
(drug therapy)
- Chemotherapy, Adjuvant
- Child, Preschool
- Combined Modality Therapy
- Cyclophosphamide
(administration & dosage)
- Etoposide
(administration & dosage)
- Humans
- Infant
- Survival Analysis
- Time Factors
- Treatment Outcome
|